Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
Victoria Snowdon(Addenbrooke's Hospital), Jonathan Fallowfield(Centre for Inflammation Research)
Cited by 64
Related Papers
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
|Nature Reviews Gastroenterology & Hepatology|2023|70
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
|Nature Medicine|2023|69
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
|Nature Medicine|2025|47
A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver
|Cell Reports Medicine|2024|14